NasdaqGS:PCVXBiotechs
Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment
Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely.
See our latest analysis for Vaxcyte.
The recent completion of enrollment in the OPUS-1 and OPUS-2 trials comes alongside strong momentum, with a 90 day share price return of 25.66% and a 1 year total shareholder return of 84.75%, while the latest share price stands at US$58.38.
If this kind of...